Tvardi Therapeutics (TVRD) Cash & Equivalents (2013 - 2026)

Tvardi Therapeutics has reported Cash & Equivalents for 14 years, with the latest figure at $19.9 million in Q1 2026.

• Quarterly Cash & Equivalents fell 41.98% year-over-year to $19.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.9 million (down 41.98% YoY) and the FY2025 annual result came in at $20.7 million, down 34.42% from the prior year.
• Cash & Equivalents eased to $19.9 million in Q1 2026 per TVRD's latest filing, from $20.7 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $63.7 million in Q4 2022 and troughed at $19.9 million in Q1 2026.
• A 5-year average of $39.8 million and a median of $42.8 million in 2022 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2025: Cash & Equivalents jumped 373.81% in 2022, then sank 58.16% in 2025.
• Over 5 years, Cash & Equivalents stood at $63.7 million in 2022, then declined by 18.77% to $51.8 million in 2023, then plunged by 38.94% to $31.6 million in 2024, then plunged by 34.42% to $20.7 million in 2025, then declined by 4.26% to $19.9 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $19.9 million, $20.7 million, and $21.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.